CPAP Therapy Does Not Appear to Improve Nonalcoholic Fatty Liver Disease in OSA
The use of CPAP alone does not appear to improve hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease and obstructive sleep apnea.
Metabolic Liver Disease
METABOLIC LIVER DISEASE
Latest Articles
FDA Fast Tracks SSAO Inhibitor for Nonalcoholic Steatohepatitis
TERN-201 is a highly-selective semicarbazide-sensitive amino oxidase inhibitor.
Novel Biomarker Panel May Allow for Noninvasive Non-Alcoholic Steatohepatitis Diagnosis
The NIS4 biomarker panel may provide a means for clinicians to avoid unnecessary liver biopsies in patients at low risk for NASH.
Significant Subset of Children With NAFLD Progress to Definite NASH, Fibrosis, and Diabetes
A team of investigators studied the relationship between changes in liver histology and changes in body mass index, dyslipidemia, and measures of glucose homeostasis in children.
Women at Lower Risk for Nonalcoholic Fatty Liver Disease But at Greater Risk for Progression
A systematic review and meta-analysis of observational studies was conducted to assess the prevalence of nonalcoholic fatty liver disease in the general population.
Updates on NAFLD: Is FMT the Treatment of the Future?
As the role of the gut microbiome in nonalcoholic fatty liver disease is explored, research has turned to fecal microbiota transplantation as a potential treatment option.
Subclinical Hypothyroidism in NAFLD Is Associated With All-Cause and Cardiovascular Mortality
Low thyroid function is associated with nonalcoholic fatty liver disease and predicted all-cause and cardiovascular mortality in this population.
Risk for Maternal, Neonatal Complications Increased With NAFLD
Women with non-alcoholic fatty liver disease have increased risks for maternal and neonatal complications.
World Trade Center First Responders have Increased Prevalence of Hepatic Steatosis
First responders to the World Trade Center attacks appear to have a much higher prevalence of hepatic steatosis than the general population.
Intravenous Choline Chloride Fast-Tracked for Intestinal Failure-Associated Liver Disease
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
Women Have Lower Overall Risk for NAFLD, But Higher Risk for Advanced Fibrosis
Women have a lower overall risk of acquiring nonalcoholic fatty liver disease (NAFLD) than men do, but a higher risk of advanced fibrosis if NAFLD status is confirmed.
Liver Forum Releases Recommendations on Diet, Exercise in NAFLD/NASH
The lack of standardized diet and exercise recommendations across NAFLD/NASH clinical trials has posed a significant challenge in understanding their impact.
Liver Forum Releases Guidelines for Assessing Patients with NASH
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
High Clinical Burden Associated With Nonalcoholic Fatty Liver Disease
The clinical burden associated with nonalcoholic fatty liver disease is high.
Updated Diagnostic Criteria for Metabolic-Associated Fatty Liver Disease
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Are Glycemic Measures in the Nondiabetic Range Linked to NAFLD?
Increased blood glucose levels, even within the nondiabetic range, are associated with increased risk for nonalcoholic fatty liver disease.
Noninvasive Scoring Systems May Identify Those at Risk for Severe Liver Disease
Noninvasive scoring systems have modest predictive ability to identify the future development of severe liver disease in patients in the general population.
Nonalcoholic Steatohepatitis Will Pose Clinical, Economic Burden
Nonalcoholic steatohepatitis (NASH) is expected to pose a significant clinical and economic burden during the next 20 years for U.S. patients with type 2 diabetes mellitus.
Patients With Nonalcoholic Fatty Liver Disease May Benefit From Daily Aspirin Use
In this prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and with lower risk for progression to advanced fibrosis.
Diabetes Drugs Compared for NAFLD Treatment
Findings of the analysis also revealed that some evidence indicates that liraglutide improves liver fat, liver function, and HbA1c, and may aid in NASH resolution and weight reduction.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
